Restore Trial

Restore-Bio is a clinical-stage biotechnology company focused on developing therapies to address aging-related diseases by targeting the mechanistic target of rapamycin (mTOR) pathway. The company's lead programs aim to enhance immune function in the elderly, particularly to reduce the incidence and severity of respiratory tract infections. By utilizing selective mTOR inhibitors, Restore-Bio seeks to reverse immune senescence and improve overall healthspan. The company was founded by industry veterans with significant experience in aging biology and drug development, leveraging insights into how metabolic pathways influence the aging process.